Aerie rises on Rhopressa data
Aerie Pharmaceuticals Inc. (NASDAQ:AERI) gained $2.56 (17%) to $17.40 on Thursday as investors digested 12-month safety and efficacy data from the Phase III Rocket 2 study of Rhopressa netarsudil ophthalmic solution ( AR-13324) to reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company plans to submit an NDA to FDA in 3Q16.
The company said no drug-related serious adverse events (AEs) occurred among the first 118 patients who received Rhopressa for 12 months, and no new adverse events developed following the trial's initial 90-day efficacy measurement period. Aerie said the most common AE was eye redness, which was generally sporadic. Other AEs included conjunctival hemorrhage, corneal deposits, blurry vision and reduced visual acuity. ...